{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=low+dose+FDC+placebo",
    "query": {
      "intervention": "low dose FDC placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=low+dose+FDC+placebo&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T22:03:48.489Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01559116",
      "title": "Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "tiotropium + olodaterol",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Respimat",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2012-03",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2015-07-16",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 4,
      "location_summary": "Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Easley",
          "state": "South Carolina"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01559116"
    },
    {
      "nct_id": "NCT01525615",
      "title": "A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Respimat inhaler",
          "type": "DEVICE"
        },
        {
          "name": "tiotropium+olodaterol (low dose)",
          "type": "DRUG"
        },
        {
          "name": "tiotropium + olodaterol (high dose)",
          "type": "DRUG"
        },
        {
          "name": "placebo to tiotropium+olodaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 404,
      "start_date": "2012-02",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-08-29",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 15,
      "location_summary": "Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Livonia",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01525615"
    },
    {
      "nct_id": "NCT05608291",
      "title": "A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Fianlimab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1564,
      "start_date": "2023-01-16",
      "completion_date": "2030-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 28,
      "location_summary": "La Jolla, California • San Francisco, California • Santa Monica, California + 21 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05608291"
    },
    {
      "nct_id": "NCT05747794",
      "title": "Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "eftilagimod alpha",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Immutep S.A.S.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2023-05-22",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 5,
      "location_summary": "Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Rock Hill",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05747794"
    },
    {
      "nct_id": "NCT01572792",
      "title": "Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium bromide",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 921,
      "start_date": "2012-04",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 179,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 146 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01572792"
    },
    {
      "nct_id": "NCT01422876",
      "title": "Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "high dose FDC",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 high dose",
          "type": "DRUG"
        },
        {
          "name": "high dose FDC placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose FDC placebo",
          "type": "DRUG"
        },
        {
          "name": "high dose BI 10773 placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose FDC",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose",
          "type": "DRUG"
        },
        {
          "name": "linagliptin",
          "type": "DRUG"
        },
        {
          "name": "linagliptin placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 10773 low dose placebo",
          "type": "DRUG"
        },
        {
          "name": "low dose BI 10773 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1405,
      "start_date": "2011-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-02",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 112,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pell City",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422876"
    },
    {
      "nct_id": "NCT01964352",
      "title": "Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "olodaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 813,
      "start_date": "2013-11",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2015-11-25",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 20,
      "location_summary": "Wheat Ridge, Colorado • Clearwater, Florida • Panama City, Florida + 17 more",
      "locations": [
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Panama City",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01964352"
    },
    {
      "nct_id": "NCT07619131",
      "title": "A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Laroprovstat",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin 1",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin 2",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat/Rosuvastatin 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat/Rosuvastatin 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Laroprovstat/Rosuvastatin 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 600,
      "start_date": "2026-08-12",
      "completion_date": "2027-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 77,
      "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07619131"
    },
    {
      "nct_id": "NCT01533922",
      "title": "Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium + Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Respimat",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 295,
      "start_date": "2012-03",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-09-15",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 8,
      "location_summary": "Torrance, California • Hartford, Connecticut • Livonia, Michigan + 5 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Livonia",
          "state": "Michigan"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Easley",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01533922"
    },
    {
      "nct_id": "NCT01533935",
      "title": "Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "tiotropium + Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        },
        {
          "name": "Olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Respimat",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 291,
      "start_date": "2012-02",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-09-15",
      "last_synced_at": "2026-09-23T22:03:48.489Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Austell",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01533935"
    }
  ]
}